Shoulder replacement implants get a lighter FDA review

In Washington, the Food and Drug Administration has given a new shoulder implant a less burdensome regulatory lane. The agency classified the shoulder joint humeral, or hemi-shoulder, ceramic head/metallic stem cemented or uncemented prosthesis as a class II device, which means it will be reviewed under special controls instead of the stricter automatic class III category. The order took effect June 5, 2026, and FDA said the classification was applicable on Dec. 16, 2022.

A narrower FDA lane

The device is meant to replace the top end of the humerus, the upper arm bone, and can be fixed with or without bone cement. FDA said the class II classification provides a reasonable assurance of safety and effectiveness while also reducing regulatory burdens, which can matter for patients waiting on new orthopedic options.

The special controls now attached to this device type are built into the codified language in 21 CFR Part 888. That gives future makers of the same kind of implant a clearer standard to work from and can make follow-on products easier to review than a brand-new device would be.